Trade Ideas
Actionable trade ideas with entry/stop/target and risk framing.
ICU Medical: Transition Growing Pains, But Fundamentals Warrant a Tactical Long (Upgrade)
Integration noise and interest expense mask positive operating cash flow and durable market positions—trade idea with clear entries, stops, and targets.
ICU Medical is navigating a heavy integration and leverage reset, producing uneven GAAP earnings but steady operating cash flow and top-tier positions...
First Hawaiian: Capital Buildout Makes 4% Yield Look Safer — Long with Tactical Stops
Improving capital and steady earnings support a shareholder-yield trade; entry near $25.50, stop below $23.50, targets $29/$33.
First Hawaiian (FHB) has quietly strengthened its capital position while maintaining a consistent quarterly dividend of $0.26. Book value per share is...
Verastem: Buy the Setback - Tactical Long After RAMP-203 Targeting Miss
Clinical disappointment creates a trading opportunity — entry, stops and targets for a high-risk, asymmetric rebound.
Verastem (VSTM) pulled back after a RAMP-203 targeting setback in KRAS G12C NSCLC. The company still has a meaningful cash position, active programs, ...
Tetra Tech (TTEK) — Buy the Weakness; Short-Term Pain, Longer-Term Optionality
Near-term guidance and headline selling have created a buying window for a cash-generative engineering services leader; entry and risk framework included.
Tetra Tech’s shares have been under pressure amid softer near-term guidance and reported institutional selling. The business still generates strong ...
Marvell: Underpriced Optionality in a Data-Heavy World
Q3 noise hides durable cash generation - use a defined long trade while sentiment re-rates
Marvell reported a mixed Q3 (fiscal 2026) where revenues of $2.07B beat on EPS headlines but missed top-line estimates. The quarter was complicated by...
Merck: Weathering a Post-2028 Slowdown — Buy on Strength of Cash Flow, Dividend, and Pipeline
A disciplined long position: the 2028-era growth concern is real, but not fatal to Merck's cash-generating franchise.
Merck trades around $106 and offers a conservative entry into a large-cap pharma with durable cash flow, a ~3.1% dividend yield and an active R&D engi...
Newmont: A Gold Major With Average Costs but Asymmetric Upside If Gold And Integration Cooperate
Buy-on-dip trade: scale into NEM around $100–104, tight stop, two upside targets tied to re-rating catalysts
Newmont (NEM) is the world’s largest gold miner with a diversified global portfolio and strong free cash flow. Recent results (Q3 FY2025) show robus...
Arcosa: Momentum, Margin Leverage and an Attractive Risk/Reward for a Long Trade
Q3 shows accelerating revenue, expanding margins and cash-flow – a tactical long with defined risk controls.
Arcosa's recent quarter shows step-function improvement in top-line and operating profitability as the company integrates acquisitions and shifts capi...
TG Therapeutics: Commercial Growth Hiding an Accounting Mirage - A Tactical Long with Tight Stops
BRIUMVI is selling, revenue is growing - but Q3 GAAP profits were driven by a one-time tax benefit. Trade it like a sprint, not a marathon.
TG Therapeutics (TGTX) is showing clear commercial traction: quarterly revenues rose from $120.9M in Q1 2025 to $161.7M in Q3 2025 and management has ...
MongoDB: Re-rating Underway — Upgrade to Buy (Follow Palantir Playbook)
AI tailwinds + improving GAAP economics justify a tactical long with clear entry, stops and targets
MongoDB reported a blowout quarter (12/02/2025) with accelerating revenue, expanding gross profit and a material step toward GAAP breakeven. Atlas str...
Dutch Bros (BROS) - Buy the Pullback; Growth Story Still Intact
High single-digit margins, strong operating cash flow and a scalable franchise model create a path to multiple expansion — trade with defined risk.
Dutch Bros is a growth-oriented drive-thru coffee operator and franchisor that is delivering solid top-line momentum, healthy operating cash flow and ...
AMD in 2026: A Tactical Long — Ride the AI GPU Wave, Watch the Valuation
Entry, stops and targets for a position trade built around AI GPU momentum and improving margins
Advanced Micro Devices looks like a high-conviction, but high-risk, long for early 2026. The company reported a meaningful sequential revenue ramp and...